143 related articles for article (PubMed ID: 7738778)
1. [Inhibitory effects of sepimostat mesilate (FUT-187) on the activities of trypsin-like serine proteases in vitro].
Nakamura K; Johmura A; Oda M; Ino Y; Uchiyama H; Ohtani H; Miyazaki H; Kurumi M; Akizawa Y; Oka T
Yakugaku Zasshi; 1995 Mar; 115(3):201-12. PubMed ID: 7738778
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments.
Aoyama T; Ino Y; Ozeki M; Oda M; Sato T; Koshiyama Y; Suzuki S; Fujita M
Jpn J Pharmacol; 1984 Jul; 35(3):203-27. PubMed ID: 6482087
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological studies on 6-amidino-2-naphthyl[4-(4,5-dihydro-1H-imidazol-2-yl)amino] benzoate dimethane sulfonate (FUT-187). I: Inhibitory activities on various kinds of enzymes in vitro and anticomplement activity in vivo.
Oda M; Ino Y; Nakamura K; Kuramoto S; Shimamura K; Iwaki M; Fujii S
Jpn J Pharmacol; 1990 Jan; 52(1):23-34. PubMed ID: 1689782
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of newly synthesized active center-directed trypsin-like serine protease inhibitors on the complement system.
Ueda N; Midorikawa A; Ino Y; Oda M; Nakamura K; Suzuki S; Kurumi M
Inflamm Res; 2000 Jan; 49(1):42-6. PubMed ID: 10778920
[TBL] [Abstract][Full Text] [Related]
5. In vivo effects of camostat mesilate on plasma kallikrein, plasma kininase II and renal kallikrein of man.
Bönner G; Babst H; Kaufmann W
Arzneimittelforschung; 1987 May; 37(5):535-7. PubMed ID: 3040018
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of ONO-3307 on various proteases and tissue thromboplastin in vitro and on experimental thrombosis in vivo.
Matsuoka S; Futagami M; Ohno H; Imaki K; Okegawa T; Kawasaki A
Jpn J Pharmacol; 1989 Dec; 51(4):455-63. PubMed ID: 2515329
[TBL] [Abstract][Full Text] [Related]
7. Effect of sepimostat mesilate on experimental venous thrombosis in rats.
Tsuruda A; Kanno S; Ohtani H; Suzuki R; Nishioka M; Koshiyama Y; Kurumi M
Thromb Res; 2001 Feb; 101(3):193-201. PubMed ID: 11228342
[TBL] [Abstract][Full Text] [Related]
8. Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension.
Maekawa A; Kakizoe Y; Miyoshi T; Wakida N; Ko T; Shiraishi N; Adachi M; Tomita K; Kitamura K
J Hypertens; 2009 Jan; 27(1):181-9. PubMed ID: 19145783
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system.
Hitomi Y; Ikari N; Fujii S
Haemostasis; 1985; 15(3):164-8. PubMed ID: 3161808
[TBL] [Abstract][Full Text] [Related]
10. Oral administration of sepimostat mesilate prevents acute alcohol pancreatic injury in rats.
Yuasa C; Irimura K; Oda M; Fukui K; Oka T
J Pharm Pharmacol; 1999 Jul; 51(7):867-71. PubMed ID: 10467964
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological studies of FUT-175, nafamstat mesilate. III. Anti-inflammatory activities of FUT-175].
Iwaki M; Oda M; Ozeki M; Ino Y; Suzuki K; Koshiyama Y; Motoyoshi A; Ogihara M; Suzuki S; Fujita M
Nihon Yakurigaku Zasshi; 1984 Oct; 84(4):373-84. PubMed ID: 6239813
[TBL] [Abstract][Full Text] [Related]
12. [Comparative studies of nafamostat mesilate and various serine protease inhibitors in vitro].
Ino Y; Suzuki K; Sato T; Iwaki M
Nihon Yakurigaku Zasshi; 1986 Dec; 88(6):449-55. PubMed ID: 2435641
[TBL] [Abstract][Full Text] [Related]
13. [The effects of FUT-175 (nafamostat mesilate) on blood coagulation and experimental disseminated intravascular coagulation (DIC)].
Koshiyama Y; Kobori A; Ogihara M; Yokomoto Y; Ohtani K; Shimamura K; Iwaki M
Nihon Yakurigaku Zasshi; 1987 Dec; 90(6):313-20. PubMed ID: 3443413
[TBL] [Abstract][Full Text] [Related]
14. The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells.
Yamaya M; Shimotai Y; Hatachi Y; Lusamba Kalonji N; Tando Y; Kitajima Y; Matsuo K; Kubo H; Nagatomi R; Hongo S; Homma M; Nishimura H
Pulm Pharmacol Ther; 2015 Aug; 33():66-74. PubMed ID: 26166259
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of serine proteases of the blood coagulation system by squash family protease inhibitors.
Hayashi K; Takehisa T; Hamato N; Takano R; Hara S; Miyata T; Kato H
J Biochem; 1994 Nov; 116(5):1013-18. PubMed ID: 7896727
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor.
Hitomi Y; Fujii S
Int Arch Allergy Appl Immunol; 1982; 69(3):262-7. PubMed ID: 6215361
[TBL] [Abstract][Full Text] [Related]
17. Hepatic and pancreatic metabolism and biliary excretion of the protease inhibitor camostat mesilate.
Beckh K; Weidenbach H; Weidenbach F; Müller R; Adler G
Int J Pancreatol; 1991; 10(3-4):197-205. PubMed ID: 1787334
[TBL] [Abstract][Full Text] [Related]
18. Treatment of ulcerative colitis with camostat mesilate, a serine protease inhibitor.
Senda S; Fujiyama Y; Bamba T; Hosoda S
Intern Med; 1993 Apr; 32(4):350-4. PubMed ID: 8358131
[TBL] [Abstract][Full Text] [Related]
19. Mechanism-based isocoumarin inhibitors for trypsin and blood coagulation serine proteases: new anticoagulants.
Kam CM; Fujikawa K; Powers JC
Biochemistry; 1988 Apr; 27(7):2547-57. PubMed ID: 3164217
[TBL] [Abstract][Full Text] [Related]
20. The synthesis of arginylfluoroalkanes, their inhibition of trypsin and blood-coagulation serine proteinases and their anticoagulant activity.
Ueda T; Kam CM; Powers JC
Biochem J; 1990 Jan; 265(2):539-45. PubMed ID: 2302184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
